Video

Will Biosimilars Impact the Cost of Specialty Drugs?

Author(s):

Davy James, Managing Editor

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Related Videos
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Related Content
GLP-1, Diabetes, Type 2 Diabetes | Image Credit: © neirfy | stock.adobe.com
January 20th 2025

ASHP Midyear: Expert Discusses GLP-1 Medications and Incretin Mimetics for Diabetes Care

Ashley Gallagher, Editor
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
December 23rd 2024

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
Woman holding pink breast cancer awareness ribbon -- Image credit: marina_li_1 | stock.adobe.com
January 20th 2025

From Abemaciclib to Trastuzumab Deruxtecan: Highlights From the 2024 San Antonio Breast Cancer Symposium

Douglas Braun, PharmD, RPh, CPH, CSP
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Red blood cells, hematology -- Image credit: Rasi | stock.adobe.com
January 19th 2025

From Blinatumomab to Venetoclax: Highlights From the 66th American Society of Hematology Annual Meeting and Exposition

Douglas Braun, PharmD, RPh, CPH, CSP
Microscopic view of metastatic breast cancer cells development and progression | Image Credit: © ratirath - stock.adobe.com
January 18th 2025

Study Shows Real-World Outcomes of First-Line Palbociclib Plus Fulvestrant in HR+, HER2– Metastatic Breast Cancer

Alexandra Gerlach, Associate Editor